Drug Profile
MGN 1404
Alternative Names: MGN-1404Latest Information Update: 29 Jun 2016
Price :
$50
*
At a glance
- Originator Mologen
- Developer Charite of Berlin; Max-Delbruck Centre for Molecular Medicine; Mologen
- Class Antineoplastics; Gene therapies
- Mechanism of Action Tumour necrosis factor alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malignant melanoma